37818-13-6|7-Deoxyadriamycinol aglycone|5,12-Naphthacenedione, 8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (S-(R*,S*))-|-范德生物科技公司

7-Deoxyadriamycinol aglycone

NMR下载 COA and HPLC MSDS下载
names：
5,12-Naphthacenedione, 8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (S-(R*,S*))-
CAS号：
37818-13-6
MDL Number：
MF(分子式)： C21H20O8 MW(分子量)： 400.38
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	7-Deoxyadriamycinol aglycone
英文别名	7-Deoxyadriamycinol aglycone;
CAS号	37818-13-6
Inchi	InChI=1S/C21H20O8/c1-29-12-4-2-3-10-14(12)20(27)16-15(18(10)25)19(26)11-7-21(28,13(23)8-22)6-5-9(11)17(16)24/h2-4,13,22-24,26,28H,5-8H2,1H3/t13-,21+/m1/s1
InchiKey	IGJIPNOEJDYNRR-ASSNKEHSSA-N
分子式 Formula	C21H20O8
分子量 Molecular Weight	400.38
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	7-Deoxyadriamycinol aglycone(CAS:37818-13-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	7-Deoxyadriamycinol aglycone is an adriamycin metabolite.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med. 1997;23(5):775-82. PubMed PMID: 9296455.

[2]Samuel L. Doxorubicin-induced cardiotoxicity. Postgrad Med J. 1995 May;71(835):318. PubMed PMID: 7596949; PubMed Central PMCID: PMC2398096.

[3] Cummings J, Milstead R, Cunningham D, Kaye S. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum. Eur J Cancer Clin Oncol. 1986 Aug;22(8):991-1001. PubMed PMID: 3770056.

[4] Dodion P, Riggs CE Jr, Akman SR, Bachur NR. Effect of hyperthermia on the in vitro metabolism of doxorubicin. Cancer Treat Rep. 1986 May;70(5):625-9. PubMed PMID: 3708610.

[5] Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep. 1986 May;70(5):619-24. PubMed PMID: 3518925.

6: Vrignaud P, Londos-Gagliardi D, Robert J. Hepatic metabolism of doxorubicin in mice and rats. Eur J Drug Metab Pharmacokinet. 1986 Apr-Jun;11(2):101-5. PubMed PMID: 3770010.7: Cummings J, Merry S, Willmott N. Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS). Eur J Cancer Clin Oncol. 1986 Apr;22(4):451-60. PubMed PMID: 3460809.8: Dodion P, Riggs CE Jr, Akman SR, Tamburini JM, Colvin OM, Bachur NR. Interactions between cyclophosphamide and adriamycin metabolism in rats. J Pharmacol Exp Ther. 1984 Apr;229(1):51-7. PubMed PMID: 6423814.9: Marshall VP, McGovren JP, Richard FA, Richard RE, Wiley PF. Microbial metabolism of anthracycline antibiotics daunomycin and adriamycin. J Antibiot (Tokyo). 1978 Apr;31(4):336-42. PubMed PMID: 26650.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开